SINOVAC Board of Directors Prevails Against Advantech/Prime’s New York Lawsuit
SINOVAC Biotech Ltd. (
NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success’ (“Advantech/Prime”) Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York.
SINOVAC Board of Directors Files Definitive Proxy Materials
The Board of Directors of SINOVAC Biotech Ltd. (
NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time).
SINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All Shareholders
The Board of Directors of SINOVAC Biotech Ltd. (
NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced several important decisions to deliver sustainable value to shareholders and strengthen the Company’s governance framework.
